Cargando…
Genetic Variation in 15-Hydroxyprostaglandin Dehydrogenase and Colon Cancer Susceptibility
BACKGROUND: 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is a metabolic antagonist of COX-2, catalyzing the degradation of inflammation mediator prostaglandin E2 (PGE(2)) and other prostanoids. Recent studies have established the 15-PGDH gene as a colon cancer suppressor. METHODS: We evaluated 15...
Autores principales: | Thompson, Cheryl L., Fink, Stephen P., Lutterbaugh, James D., Elston, Robert C., Veigl, Martina L., Markowitz, Sanford D., Li, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661460/ https://www.ncbi.nlm.nih.gov/pubmed/23717544 http://dx.doi.org/10.1371/journal.pone.0064122 |
Ejemplares similares
-
15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury
por: Kim, Byeong Woo, et al.
Publicado: (2021) -
miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer
por: Monteleone, Nicholas J., et al.
Publicado: (2019) -
Decreased Expression of 15-hydroxyprostaglandin Dehydrogenase in Gastric Carcinomas
por: Jang, Tae Jung, et al.
Publicado: (2008) -
Relationship between 15-hydroxyprostaglandin dehydrogenase and gastric adenocarcinoma
por: Kang, Jae Hyun, et al.
Publicado: (2014) -
Downregulation of 15-hydroxyprostaglandin dehydrogenase in hormone-resistant breast cancer
por: Cummings, M, et al.
Publicado: (2008)